- Renal Solutions Announces Opportunity for Patients to Participate in
Research Aiming Toward Improved Future Dialysis Options -
WARRENDALE, Pa., Nov. 7 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services, today announced that a home use clinical research trial has begun using sorbent technology. The study presents the opportunity for 25 dialysis study participants to evaluate the ability to self-administer extended duration dialysis in the home when using the Allient(R) Sorbent Hemodialysis System. In this study, the use of the Allient System in the home is an investigational use.
The Allient System enables hemodialysis using only 1.5 gallons (6 liters) of drinking water to provide a convenient therapy option requiring no plumbing modifications to a person's home. It is the only system that uses Sorbent Management for Advanced Renal Replacement Therapy (SMARRT(TM)). SMARRT therapy is based on more than 35 years of proven dialysis, using a gentle, patient-driven technology that enables flexible treatment options including extended duration dialysis therapy -- resulting in greater patient freedom and control.
"Our current participating clinical trial sites demonstrate their commitment to improving future patients' quality of life by taking part in a study like this," said David Vanella, Renal Solutions Vice President of Regulatory Affairs. "It's the drive to discover and apply new technologies that ultimately makes future alternative therapies available and accessible to patients."
The success of this trial may permit dialysis providers in the future to offer an alternative system and therapeutic modality to their patients. In the trial, study participants are trained and transitioned during the initial 8 weeks from self-care in a dialysis clinic setting to 8 weeks of dialysis self- administration in the home.
"Extended duration dialysis in the home is not a new concept and its potential benefits are well-known, including increased stamina, enhanced appetite and improved quality of life as just a few of the improvements this form of treatment can offer," said Renal Solutions CEO Peter M. DeComo. "The home modality has been out of vogue in part because available dialysis equipment hasn't been suited to the home. But it's on its way back. This trial may mark a tremendous step forward for people living with chronic kidney failure in the future."
"In addition to home hemodialysis being a proven alternative to in-center dialysis, at-home dialysis offers individuals more freedom and control in their lives," said Dr. Mark Rohrscheib, University of New Mexico Health Sciences Center. "The convenience of a dialysis technology that uses only a small amount of drinking water for each treatment is a tremendous advantage for home dialysis. Patients interested in new modalities will be excited to learn about this trial."
"We're pleased to be part of a trial that may introduce new options for our home dialysis patients," said Brigitte Schiller, MD, Director of Research, Satellite Healthcare, Mountain View, Ca. "This trial may further bring to light the benefits of extended duration dialysis."
Active recruitment has begun at multiple sites with subjects continuing to enroll in the study. Renal Solutions is working with a group of nephrologists and patient-focused dialysis facilities to conduct this trial. Individuals who are interested in contributing to a movement that is intended innovate the way chronic kidney failure is treated should ask their doctors about participating local research sites.
Patient-focused dialysis centers with certified home programs that are interested in learning more about this home trial should contact Mr. Vanella, (724) 772-6900, ext. 140.
About Renal Solutions, Inc.
Renal Solutions, Inc., a medical device and healthcare service company, is commercializing the Allient(R) Sorbent Hemodialysis System, a revolutionary technology/service solution for the chronic and acute dialysis market. The Allient System, brings SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) therapy to the dialysis field, opening new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased flexibility and convenience benefits.
|SOURCE Renal Solutions, Inc.|
Copyright©2007 PR Newswire.
All rights reserved